Article
Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR.
La Tunisie medicale - 1 Mar 2016
Abdelhamid Emna, Besbes Sawsen, Renneville Aline, Nibourel Olivier, Helevaut Nathalie, Preudhomme Claude, Soua Zohra
Abstract excerpt
BACKGROUND: With the growing importance of minimal residual disease (MRD) monitoring and the recent discover of IDH mutations in acute myeloid leukemia (AML), the quantification of this molecular marker provides the possibility to monitor the disease progression and the therapy efficacy. OBJECTIVE: The aim of this study is to assess the MRD in AML for the first time with IDH1 and IDH2 gene mutations in 15 AML...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.